IV ketamine for Lake Worth Beach — psychiatry-supervised, integrated with therapy.

RECO Health's Delray Beach campus is fourteen miles and twenty-two minutes south of downtown Lake Worth Beach — close enough for clients in Bryant Park, College Park, and Parrot Cove to complete a Monday/Wednesday/Friday induction without relocating. Every ketamine visit is psychiatry-supervised, dose-standardized at 0.5 mg/kg over forty minutes, and paired with next-day integration therapy drawing from CBT, ACT, and EMDR. RECO Health offers both IV ketamine and Spravato so the clinical and insurance question can be answered in the same consult, not after a wasted trial.

Lake Worth Beach sits fourteen miles up A1A from RECO Health’s Delray Beach campus — roughly a twenty-two-minute drive outside of season, longer once winter traffic thickens through the coastal corridor. Clients from Bryant Park, College Park, Parrot Cove, Mango Groves, and downtown Lake Worth commute to our psychiatry-supervised IV ketamine program a few days a week without giving up the community they live in. Ketamine at RECO Health is a medical treatment for treatment-resistant depression, refractory PTSD, and acute suicidality — delivered by a psychiatrist, integrated with structured therapy, and never operated as a standalone infusion clinic.

Why ketamine works within hours instead of weeks

Ketamine is a non-competitive NMDA receptor antagonist. Blockade of NMDA receptors on GABAergic interneurons produces a downstream surge in glutamate that activates AMPA receptors, drives brain-derived neurotrophic factor (BDNF) release, and produces rapid synaptogenesis in the prefrontal cortex and hippocampus. Those cellular changes correlate clinically with lifted mood, reduced suicidal ideation, and improved cognitive flexibility — often measurable within hours of the first infusion.

Compare that mechanism to a standard SSRI like sertraline, an SNRI like venlafaxine, or an atypical augmentation strategy with aripiprazole or lithium. Monoamine reuptake inhibition takes four to six weeks to translate into measurable PHQ-9 change, and that timeline is untenable for a patient in acute suicidal crisis and inadequate for one who has already failed three or more antidepressant trials. Ketamine’s role in the treatment-resistant depression pathway isn’t as a first-line agent — it belongs there because when six weeks isn’t available, ketamine works in seventy-two hours.

The anti-suicidal effect of ketamine appears to be at least partially independent of the antidepressant effect. That distinction matters when a patient presents with active suicidal ideation and a plan, and it is the specific reason Spravato (esketamine) carries an FDA indication for major depressive disorder with acute suicidal ideation as well as for treatment-resistant depression.

The 40-minute infusion, monitored recovery, and six-session induction

Each ketamine visit runs roughly two hours end-to-end. Intake vitals are taken, IV access is established, and 0.5 mg/kg of racemic ketamine is infused over forty minutes on a programmable pump. Weight-based dosing is the default; occasional titration up or down happens based on prior response and tolerability. Throughout the infusion, blood pressure, heart rate, and oxygen saturation are tracked continuously, and dissociative symptoms are assessed with the Clinician-Administered Dissociative States Scale (CADSS).

The infusion is followed by thirty to sixty minutes of monitored recovery in a quiet room. Blood pressure typically rises transiently during the infusion — expected, not an emergency, and it resolves without intervention in the great majority of patients. Clients are not permitted to drive after a session; a family member, rideshare, or sober-living transport is arranged in advance and confirmed before the infusion begins.

The induction series is six infusions across two to three weeks, most often on a Monday, Wednesday, and Friday cadence. That window is where sustained response either consolidates or doesn’t; in properly selected patients with treatment-resistant depression, response rates by the end of induction run in the 50-70% range in the published literature, with responders typically identifiable by session three or four.

Integration therapy is what makes response durable

Ketamine opens a neuroplastic window. Therapy determines whether the patient walks through it. RECO Health’s protocol pairs the infusion series with structured integration sessions — typically the day after each infusion, while the neurochemical window is still open and the material that surfaced during the session remains accessible.

Integration draws from CBT for depressive cognition, ACT for values-based reorientation, EMDR when the underlying material is trauma-driven, and DBT skills when emotion regulation is the limiting factor. The therapist works with what emerged during the dissociative experience — insights, emotional material, half-buried memories — and consolidates those shifts into durable behavioral change. Motivational interviewing supports adherence between sessions when ambivalence about ongoing treatment surfaces.

The literature on this point is consistent: ketamine delivered without integration produces shorter response duration and higher relapse rates than ketamine paired with psychotherapy. A standalone infusion clinic treats ketamine as a drug. RECO Health treats it as one leg of a three-legged protocol — infusion, integration, and medication management — and durability of response reflects the difference.

IV ketamine vs Spravato and how we decide

IV racemic ketamine is used off-label for depression and is self-pay in nearly all cases. Spravato (esketamine), the intranasal S-enantiomer, is FDA-approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation, and it is covered by most commercial insurance under a Risk Evaluation and Mitigation Strategy (REMS) protocol.

The choice between them is clinical and financial. Spravato is the answer when insurance coverage is the deciding factor, when a twice-weekly-for-four-weeks induction schedule is workable, and when the patient’s phenotype fits the FDA-approved indication. IV ketamine is the answer when dose flexibility matters — for example, in patients who under-respond to fixed intranasal dosing — when response quality favors the IV route, or when a compressed schedule is clinically necessary because of acuity.

RECO Health offers both. The decision is made during the psychiatry consult after documented review of prior antidepressant trials, response patterns, psychiatric comorbidities, and insurance status. Neither route is universally superior; both are tools within the same treatment-resistant depression pathway, and clients begin our ketamine therapy program only after that decision is made explicitly with the treating psychiatrist.

What to expect at your first visit from Lake Worth Beach

The first appointment is a psychiatric consultation, not an infusion. Expect a full diagnostic interview, medication reconciliation, and baseline symptom measurement with the PHQ-9 for depression and the GAD-7 for anxiety. Prior antidepressant trials — sertraline, escitalopram, venlafaxine, bupropion, mirtazapine, aripiprazole augmentation, lithium — are documented with dose, duration, and response.

Cardiovascular history is reviewed with particular attention to blood pressure control. Uncontrolled hypertension, active untreated substance use disorder, and a history of primary psychotic disorder are relative or absolute contraindications and are worked through case-by-case. Basic labs and an EKG may be ordered when clinically indicated. Only after the psychiatric evaluation is complete — usually the same day or within a week — is the induction series scheduled. If Spravato is the better clinical and financial fit, REMS enrollment paperwork is initiated at that same consult.

Insurance and getting to RECO Health from Lake Worth Beach

The drive from Lake Worth Beach to RECO Health’s Delray Beach campus is fourteen miles down I-95 or A1A — twenty-two minutes in ordinary traffic, thirty to forty during season. Most Lake Worth Beach clients complete the six-infusion induction on a Monday/Wednesday/Friday schedule and step down to weekly integration therapy and monthly maintenance boosters as response consolidates.

RECO Health is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Spravato is billed through medical benefits and typically requires prior authorization documenting at least two failed antidepressant trials at adequate dose and duration. IV ketamine is self-pay in most cases and can be structured as a package across the induction series. Admissions can complete a benefits verification and schedule the initial psychiatry consultation within the same business week — most Lake Worth clients are in front of a psychiatrist within days of the initial call.

Serving residents of: Bryant Park, College Park, Mango Groves, Parrot Cove, downtown Lake Worth.